v3.26.1
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2024
USD ($)
Feb. 28, 2026
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Apr. 30, 2024
USD ($)
Jun. 30, 2023
Jun. 30, 2022
USD ($)
Program
PerformanceObligation
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Accounts receivable, reserve for credit losses     $ 0           $ 0   $ 0   $ 0    
Revenue                 $ 9,839,000 $ 63,745,000 $ 24,362,000 $ 81,144,000      
Common stock, shares issued | shares     8,584,309           16,576,205   16,576,205   8,584,309    
Common stock value issued     $ 9,000           $ 17,000   $ 17,000   $ 9,000    
Common stock, par value | $ / shares     $ 0.001           $ 0.001   $ 0.001   $ 0.001    
Vaxcyte, Inc.                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Additional milestone payment                 $ 60,000,000   $ 60,000,000        
2015 License Agreement | Blackstone Life Sciences | Royalty                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Revenue interest percentage             4.00%       4.00%   4.00%    
Supply Agreement | Vaxcyte, Inc.                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Reimbursements expenses accruals     $ 12,700,000           7,100,000   $ 7,100,000   $ 12,700,000    
Reimbursements expenses                 100,000 800,000 300,000 1,100,000      
Astellas License and Collaboration Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Number of target programs | Program               3              
Transaction price               $ 90,000,000              
Estimated service period               4 years              
Recognition of up front payment               $ 89,100,000              
Nonrefundable, non-creditable upfront payment receivable                             $ 90,000,000
Number of performance obligations | PerformanceObligation               4              
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate                 422,500,000   422,500,000        
Revenue                 9,637,000 7,415,000 24,145,000 24,294,000      
Constrained variable consideration   $ 10,000,000 7,500,000 $ 7,500,000                      
Contingent payment recognized as deferred revenue   10,000,000 7,500,000 7,500,000                      
Astellas License and Collaboration Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Revenue   9,100,000 6,600,000 5,700,000 $ 17,800,000       4,177,000 5,410,000 16,135,000 18,368,000      
Astellas License and Collaboration Agreement | Minimum                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Total transaction price   105,000,000 97,500,000 90,000,000                      
Astellas License and Collaboration Agreement | Maximum                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Total transaction price   $ 115,000,000 105,000,000 $ 97,500,000                      
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Recognition of up front payment               $ 900,000              
Astellas Agreement and CFE Supply Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Deferred revenue     $ 12,600,000           6,500,000   6,500,000   $ 12,600,000    
Ipsen Agreement                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Total transaction price                       50,400,000      
Revenue                 0 56,069,000 0 56,357,000      
Nonrefundable, non-creditable upfront payment                       50,000,000      
Common stock premium $ 400,000         $ 400,000       400,000   400,000      
Upfront license fee           $ 50,000,000                  
Common stock, shares issued | shares                           482,738  
Common stock value issued                           $ 25,000,000  
Common stock, par value | $ / shares                           $ 51.79  
Fair market value of common stock issued $ 24,600,000                            
Ipsen Agreement | Ongoing Performance Related to Unsatisfied Performance Obligations                              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                              
Revenue                 $ 0 $ 50,429,000 $ 0 $ 50,429,000